New opportunities with biologic treatments in pediatric allergic and respiratory diseases.
Pediatr Allergy Immunol
; 33 Suppl 27: 8-10, 2022 01.
Article
em En
| MEDLINE
| ID: mdl-35080293
ABSTRACT
In the last 20 years, the introduction of monoclonal antibodies has dramatically changed allergic diseases. At present, several monoclonal antibodies are approved for treating asthma, atopic dermatitis, chronic spontaneous urticaria, and chronic sinusitis with nasal polyps in children. Biologics have also changed the management of these diseases in the pediatric population, tending toward personalized medicine based on the type-2 inflammatory pattern.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Asma
/
Produtos Biológicos
/
Pólipos Nasais
/
Dermatite Atópica
/
Hipersensibilidade
Limite:
Child
/
Humans
Idioma:
En
Revista:
Pediatr Allergy Immunol
Assunto da revista:
ALERGIA E IMUNOLOGIA
/
PEDIATRIA
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Itália